Melinda Dunlap, MD
Hematology & Oncology · Tulsa, OKNPI 1609096668
Payments from drug & device makers
Across 122 payments — averaging $1423.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$168K
- Bristol Myers Squibb$3K
- AstraZeneca$558
- Pfizer$299
- Daiichi Sankyo Inc.$269
- Gilead$265
- plus $1K from 28 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 4 | $167,727 |
| Bristol Myers Squibb | 5 | $3,357 |
| AstraZeneca(2 entities) | 19 | $558 |
| Pfizer | 23 | $299 |
| Daiichi Sankyo Inc. | 7 | $269 |
| Gilead | 4 | $265 |
| Novartis | 9 | $172 |
| Sanofi | 5 | $110 |
| E.r. Squibb & Sons, L.L.C. | 5 | $92 |
| AbbVie | 4 | $88 |
| Johnson & Johnson | 4 | $87 |
| Janssen Scientific Affairs, LLC | 1 | $77 |
| Seagen Inc. | 4 | $68 |
| AVEO Pharmaceuticals, Inc. | 2 | $50 |
| Beigene USA, Inc. | 2 | $46 |
| GSK | 2 | $36 |
| Geron Corporation | 2 | $35 |
| Astellas Pharma US Inc | 2 | $34 |
| Regeneron Healthcare Solutions, Inc. | 2 | $32 |
| Eisai Inc. | 2 | $29 |
| Beone Medicines USA, Inc. | 1 | $26 |
| Myovant Sciences Inc. | 1 | $24 |
| Pharmaessentia USA Corporation | 1 | $23 |
| Exelixis Inc. | 1 | $20 |
| Agios Pharmaceuticals, Inc. | 1 | $19 |
| Bayer | 1 | $17 |
| Amgen | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Ipsen Biopharmaceuticals, Inc | 1 | $16 |
| Stemline Therapeutics Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $15 |
| Intuitive Surgical | 1 | $13 |
| Lilly USA, LLC | 1 | $13 |
| Puma Biotechnology, Inc. | 1 | $12 |
How this compares
$173,676 in reported general payments places this provider in the 80th percentile of 118 hematology & oncology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Tulsa
- Kevin WeibelTulsa$1.7M
- Scott ColeTulsa$644K
- Mark OlsenTulsa$331K
- Caleb ScheckelTulsa$232K
- Charles StrnadTulsa$153K
- Hassan KaleemTulsa$137K
- Charles TaylorTulsa$59K
- Ali MoussaTulsa$19K
- Alan KellerTulsa$10K
- Supriya KoyaTulsa$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.